apsulis

BrainTale, a medtech from Paris Hospitals, accelerates its development in the French Grand Est region  with the presentation in Strasbourg of the results of its exploratory study on the relevance of its clinically validated biomarkers platform for diagnosis and follow-up of patients with amyotrophic lateral sclerosis (ALS or Charcot disease) and the announcement of the signing of a strategic partnership with the University Hospitals of Strasbourg.

On the occasion of the Journées de Neurologie en Langue Française in Strasbourg, BrainTale, the French white matter specialist, presents first encouraging results on the value of its white matter quantification platform for early detection of amyotrophic lateral sclerosis, offering better monitoring of disease progression and also potentially in the long term the possibility to increase the chances of success of clinical developments by precisely identifying the different sub-forms of the disease and helping to evaluate the effectiveness of drug candidates. Long underestimated in neurosciences, white matter represents 80% of our brain, playing a key role in its proper functioning, development, and aging, whether normal or pathological. The careful examination of white matter can become a game-changer for many diseases including Amyotrophic lateral sclerosis.

What is Amyotrophic Lateral Sclerosis?

Amyotrophic lateral sclerosis (ALS), also known as Charcot’s disease, is characterized by a progressive and irreversible degeneration of motor neurons that allow the body’s movements to be controlled. Patients with ALS gradually experience symptoms such as cramps, muscle contractions, and strain. Over time, within two to five years of initial diagnosis, the whole body is paralyzed, including the respiratory muscles, resulting in inevitable death. Fatal in 100% of cases, the disease affects 50,000 patients in Europe*.
Today, doctors deplore a late and long journey to precisely diagnose the condition an average of one year after the first symptoms, thus delaying the time to initiate symptomatic care, largely suboptimal.

How can BrainTale be a game-changer?

BrainTale is now convinced that accurate and regular analysis of white matter can become a decisive indicator in the management of patients with neurological diseases, notably ALS beyond the benefits demonstrated in intensive care. In the case of ALS, literature data highlight white matter alterations even before the onset of symptoms and is, moreover, correlated precisely to clinical score and progression of the disease. The BrainTale-care platform, a CE marked digital medical device, is already available in selected centers. Non-invasive and easily implementable in hospitals, the BrainTale-care platform can therefore become a decisive tool for healthcare professionals in disease management.

The preliminary study presented today offers encouraging perspective in the diagnosis and disease  monitoring for ALS patients.

“This data in amyotrophic lateral sclerosis strengthens our approach in the potential of our platforms to provide patients with concrete, innovative and relevant solutions”comments Vincent Perlbarg, co-founder and CSO of BrainTale.

This study, conducted under the direction of Dr Pierre-François Pradat, neurologist at the Pitié-Salpêtrière Hospital in Paris, is the result of the SOM-ALS Inserm-sponsored trial (NCT03694132) and presented by Hugo Kermorvant. The poster is entitled Evaluation of a clinically validated MRI analysis web platform for obtaining biomarkers in ALS and is available here:
https://jnlf2022.process.y-congress.com/ScientificProcess/Schedule/?setLng=fr >> Posters >> Sclérose
latérale amyotrophique.

“These encouraging results are a strong signal to highlight the value of innovative neuroimaging tools for the management of patients with ALS” said Dr. Pradat. “Having to be confirmed on broader cohorts, this is a significant opportunity to change the situation in disease management”, he adds.

A strategic partnership with the Strasbourg University Hospitals
Strasbourg University Hospitals have been convinced of Braintale’s platforms value, becoming the first nonparisian institution equipped with the Braintale-care platform. The platform, with its two CE-marked modules under the Medical Device Regulation (MDR) in force in the European Community – brainQuant and brainScore coma – are thus available to clinicians to offer optimal patient management.

Professor Julien Pottecher, anesthesiologist at the University Hospitals of Strasbourg comments “The clinical interest of the Braintale-care platform and its expected benefits for patient management convinced us to establish this strategic relationship with Braintale. This digital innovation in intensive care could significantly change the situation in hospitals”.

“Braintale continues to shift imaging towards diagnosis and clinical prediction, opening up opportunities to contribute alongside other practitioners to optimal patient management”, adds Professor Stéphane Kremer, neurologist.

Julie Rachline, co-founder and president of LallianSe, Braintale’s CEO”the combination of these encouraging results presented today in Strasbourg and the deployment of our solutions at Strasbourg University Hospitals is for BrainTale a key step in our ambitious trajectory”.

*(Epidemiology of amyotrophic lateral sclerosis: an update of… : Current Opinion in Neurology (lww.com), What is ALS? | EUpALS ;
https://cordis.europa.eu/project/id/259867/fr

About the University Hospitals of Strasbourg
Alsace’s largest employer, the HUS are composed of five establishments. They ensure a mission of care but also of research and teaching. Their specificity as Regional University Hospital (CHRU) They are able to provide routine care to the population of Strasbourg and its surroundings as well as take charge of patients with complex or rare diseases from more distant geographical areas.

About BrainTale
BrainTale is an innovative company dedicated to the decryption of white substance to allow better management in neurology and resuscitation with clinically validated prognostic solutions. With sensitive and reliable measurements of white matter microstructure alterations, Braintale offers a digital biomarker platform to help in clinical decisionmaking. Braintale allows identification of patients at risk, early diagnosis and monitoring of disease progression and treatment effectiveness. Based on more than 15 years of development, BrainTale’s products are developed to meet the medical needs and expectations of healthcare professionals and patients. Since its creation in 2018, the company has implemented a comprehensive quality management system and is now ISO 13485 certified 2016, with a suite of products available on the European market. For more information, please visit www.braintale.eu.

Contacts
Braintale – Julie Rachline, CEO julie.rachline@braintale.eu +33 6 62 42 03 58
Braintale Press – Anna Casal casal.anna@gmail.com +33 6 50 61 55 71
HU Strasbourg Presse – Hélène Braeuner presse@chru-strasbourg.fr +33 3 88 11 64 12

BRAINTALE, whose head office is 11 rue de l’Académie 67000 – STRASBOURG, is registered in the Trade and Companies Register under number 840 995 138 RCS STRASBOURG

Last update : 09/19/2022